Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cancerologia de Mexico
• Treatments: Carboplatin

Criteria

Inclusion Criteria:

• Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)

• Candidates for treatment with carboplatin plus paclitaxel 1st line

• Performance status (ECOG 0-2)

• Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)

• Normal renal ultrasound prior to initiation of treatment

Exclusion Criteria:

• Patients with renal impairment (KDOQI 3-5)

• Patients who do not have computed tomography study at baseline

• Uncontrolled blood pressure (> 140 mmHg)

• Uncontrolled diabetes (> 130 mg / dL)

• Obstruction in kidney (s) or ureter (s)

• Dehydrated patients

• Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.> 1 month)